Pembrolizumab monotherapy for previously treated metastatic HER2-negative breast cancer with germline APOBEC3B deletion: results of the phase II AUROR study.
Ho GF, Lee SC, Bustam AZ, Alip A, Abdul Satar NF, Saad M, Malik RA, Lim SE, Ow SGW, Wong A, Chong WQ, Ang YLE, Lee AWY, Hasan SN, Tuan Zaid N, Law KB, Toh YY, Tan HC, Selvam B, Lim J, Pan JW, Teo SH.
Ho GF, et al. Among authors: hasan sn.
Lancet Reg Health West Pac. 2025 Jul 13;60:101637. doi: 10.1016/j.lanwpc.2025.101637. eCollection 2025 Jul.
Lancet Reg Health West Pac. 2025.
PMID: 40697533
Free PMC article.